This Company Can Secure Your E-Mails - and Your Financial Future

If you want to become a high-tech millionaire, sometimes all you have to do is check your email.

Let me explain. In four days, I received two emails purporting to help me with e-commerce issues.

Good thing I didn't open them. Each one was a "phishing expedition."

That's the term we use when you get an email that looks legit but actually is an attempt to steal your financial data or launch an attack on your computer.

The reason why I am telling you this now is that odds are pretty good you will receive at least one yourself. And during the frenzy that is Christmas shopping, you may get careless – and hacked.

So, at the very least, today's chat may save you hundreds, maybe even thousands of dollars.

It also will help keep your key financial data secure from cyber thieves who have used bogus emails to do at least $12.5 billion in financial damages.

Here's Why I Completely Shifted My Stance on Government Mandates

You know, all of my adult life, I've been a hard-hitting fiscal conservative.

If you'd come to me two or three years ago and said there's a new government mandate – a California government mandate – that Michael Robinson was going to love and endorse, I would've laughed you out of the room.

But, my new research has completely shifted my stance.

How This One Tech Company Can Redefine Your Wealth

Now it can finally be said – I was right and Wall Street and the media were dead wrong.

In fact, if you listened to those alleged experts, you would have left a lot of money on the table in this incredible bull market.

Here's why I say that; for at least the last seven years, time and again we have seen the Street and the media suggest that a tech rout was at hand.

I often felt like the lone voice in the crowd when I would remind you, reader, that the road to wealth is paved with tech.

So, you can imagine my reaction when I saw a recent story in the Wall Street Journal that said tech stocks are on the verge of their best year since the bull market began in 2009.

How to Cash In on the Biggest Medical Breakthrough of the Decade

Imagine if all it took to treat a case of cancer was taking out the trash.

Now, I want you to imagine that your body could do it all for you.

Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.

Here's the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as "degraders."

Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body's own molecular trash disposal systems.

This is one of the most exciting breakthroughs I've come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.

You Can Double Your Money Fighting the $1.1 Trillion Disease Killing America

I recently got the kind of news that no child wants to hear about an aging parent.

Here's the thing: I count my blessings that my dad lived so long. After all, he's a retired Marine Corps captain who saw three tours of combat, one in Korea and two in Vietnam.

Honestly, he's lucky he lived as long as he did. But that still doesn't make the aging process any easier, at least not on the body.

He recently had a second knee replacement that didn't go as well as planned. He also has swelling of the feet. His mobility is not all that great, and he can't drive right now.

At 86, he recently learned he has congestive heart failure. That's a condition in which the heart doesn't pump as strongly as it should, leading to a buildup of fluids.

As such, my dad is part of a huge trend in America. Fact is, according to the American Heart Association, cardiovascular disease is set to have an economic impact of $1.1 trillion by 2035.

And today, I want to reveal a life sciences firm that is bringing badly needed relief to millions of heart patients – and show you five reasons why it's set to double in as little as three-and-a-half years…

The Answer to Big Pharma's Biggest Problem Could Double Your Money in Just Three Years

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world's largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That's a one-in-ten shot.

With such daunting data, it's no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I've uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector's success.

It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure.

Why Amazon Stock Could Hit $3,000 Per Share

By now, I think it's safe to say that Jim Cramer was dead wrong.

And I was right on the money.

Here's the thing. I remember very clearly the day that Amazon.com Inc. crossed the $1,000 mark on May 31, 2017.

Cramer, the host of CNBC's "Mad Money" looked at the price and slammed it. He said that "psychologically" $1,000 is a lot to pay for a stock he felt was getting ahead of itself.

As the saying goes, that was then and this is now.

No doubt, the tech leader hit a rough patch late last year with the rest of the market. And it has come under fire recently as part of the Big Tech backlash.

Yet, below-expected earnings reports for Q2 and Q3 of this year could only pull Amazon down into the $1,700 range, still far above what Cramer was worrying about.

Not only that, but the "King of E-commerce" is well-positioned for another historic moment. It's roughly 15% away from having a $1 trillion market cap, and most of that would just be regaining lost ground.

And today, you'll see why I still firmly believe the stock will hit at least $3,000 a share – and likely much, much more than that…

The Small-Cap Backend Cannabis Play Set to Disrupt a $1.2 Trillion Global Industry

I'm having a great day – nothing hurts.

Trust me, that's no minor thing in my life. See, I've suffered from chronic lower back pain since I was 15, and my neck has hurt since my early 20s.

For years, I have relied on Advil Liqui-Gels and Biofreeze menthol rub for daytime relief. I also took muscle relaxants to combat night spasms that would keep me awake.

However, those pains are quickly becoming just memories because I have found what is, so far, giving me amazing results.

It's a substance the human race has used for centuries. It's all natural and very effective. It's also a compound that is sweeping 33 states and the District of Columbia.

Of course, I'm talking about cannabis.

Make no mistake, the substance that used to be demonized in the United States has great medicinal properties.

In fact, I'll be talking about how to profit from medical aspects of marijuana at the National Institute for Cannabis Investors (NICI) in Las Vegas on Thursday.

These 3 Tech Stocks Will Keep Crushing the Market

My wife says that at the rate I'm going, we're going to have to buy a new table.

Let me explain. My job as your tech analyst is to go beyond the headlines and find great tech stocks that can absolutely crush the market – in good times and in bad.

And that often means pounding the table for the global tech ecosystem in general, and for market rippers in particular.

That's exactly what I did back on Jan. 11. You may not recall it, but in my mind's eye, it's as if it were just yesterday.

At the time, the tech-centric Nasdaq had entered bear market territory, defined as a 20% drop from a recent high. I said it was "fear and not fundamentals" that was driving the market lower.

I then listed three beaten-down tech leaders I said were poised for big rebounds.

Today, I'm following up let you know – all three just crushed it, as I'll show you.

Why Amazon Could Hit $3,000 Per Share

By now, I think it's safe to say that Jim Cramer was dead wrong.

And I was right on the money.

Here's the thing. I remember very clearly the day that Amazon.com Inc. (AMZN) crossed the $1,000 mark on May 31, 2017.

Cramer, the host of CNBC's Mad Money looked at the price and slammed it. He said that "psychologically" $1,000 is a lot to pay for a stock he felt was getting ahead of itself.

As the saying goes, that was then and this is now.

No doubt, the tech leader hit a rough patch late last year with the rest of the market. And it has come under fire recently as part of the Big Tech backlash.

Yet, as the firm prepares to report earnings later this week, the stock is once again trading in the $2,000 range, double what Cramer was worrying about.

Not only that, but the "King of E-commerce" is just shy of hitting another historic moment. It's roughly 2% from having a $1 trillion market cap.

And today, I'm going to show you why I still firmly believe the stock will hit at least $3,000 a share – and likely much, much more than that…